Prognotic impact of serum follistatin in patients with hepatocellular carcinoma.

摘要: Background and aim Follistatin (FST) is a glycoprotein expressed in most organs, which interacts with activins or other members of the transforming growth factor beta family. Recently, several reports have shown that FST regulates variety processes during tumor progression. Here, serum patients liver diseases was measured, its clinical utility as biomarker assessed. Methods Serum collected from 162 (91 hepatocellular carcinoma [HCC], 43 cirrhosis, 28 chronic hepatitis) well 16 healthy volunteers. quantified by enzyme-linked immunosorbent assays, levels were compared parameters including survival HCC patients. Results Median HCC, hepatitis, volunteers 1168, 1606, 1324, 1661 pg/mL, respectively, not significantly different. In patients, higher associated greater age, hepatitis C virus antibody-negativity, large size, g-glutamyl transpeptidase, des-gamma carboxyprothrombin presence portal vein thrombus. Survival high shorter than for those low (P = 0.004). Multivariate analysis revealed addition to size thrombus, independently correlated poor prognosis (hazard ratio 2.41, 95% confidence interval 1.16-5.00, P 0.02). Conclusions are could represent predictive this disease.